Skip to main content

Interventional Cardiology

Coronary Therapies

The medical device industry’s most complete portfolio of PCI products

Together we can strengthen quality outcomes, increase operational efficiencies, and improve financial health in your cardiovascular service line (CVSL).

30%

Of all U.S. PCI patients present with calcium

20%

Of all U.S. PCIs are complex

~60%

Higher reimbursement for complex PCI vs. standard PCI**

Medical professional helping a paitent in a wheelchair down a hallway.

If complex PCI is a focus, we can help. As the market leader in Interventional Cardiology, Boston Scientific brings the most comprehensive portfolio of PCI products, education programs, and healthcare solutions and partnerships. Work with us to:

The market leader in coronary therapies

SYNERGY™ Bioabsorbable Polymer (BP) Stent Systems

Putting the patient first, we offer all the products, programs and solutions designed to help your CVSL strengthen quality outcomes, increase operational efficiencies, and improve financial health.

An enlargement of the SYNERGY XD device

SYNERGY™ XD
The next generation SYNERGY Bioabsorbable Polymer (BP) Stent. Equipped with an innovative delivery system that offers increased pushability and trackability to make optimal healing even more deliverable

Explore SYNERGY XD

SYNERGY™ XD 48 mm
The first and only 48 mm DES in the U.S. Designed to address the unique needs of long lesions.

Explore SYNERGY XD 48mm

SYNERGY MEGATRON™
Purpose-built for large, proximal vessels. The single versatile stent model can expand 2.5 mm, from 3.5 mm to 6.0 mm, allowing you to size to the distal vessel and taper up proximally.

Explore SYNERGY MEGATRON

Leading on Studying Short DAPT

The SYNERGY BP Stent is indicated for use in high bleeding risk patients with short DAPT labeling. Boston Scientific is leading the way in supporting short DAPT studies with the SYNERGY BP Stent in a variety of patient populations and DAPT durations.

.0% ST

0-month DAPT
ASET Trial1

3 months post PCI

.0% ST

1 month DAPT
SENIOR Trial2

From 1-12 months

.9% ST

1 month DAPT
POEM Trial3

At 1 year

.2% ST

3 month DAPT
EVOLVE Short DAPT4

From 3-15 months

Learn more about the SYNERGY BP Stent5

A full portfolio built for modern PCI

SYNTAX II trial utilizes contemporary PCI tools and techniques producing CABG-like outcomes.

Tools to diagnose, prep, treat, and validate because no two patients are the same.

PCI Guidance

AVVIGO™
Guidance System II

COMET II™
FFR Pressure Guidewire

OPTICROSS™ HD
Imaging Catheters

Complex PCI

ROTAPRO™
Rotational Atherectomy System

AVVIGO™
Guidance System II

SENTAI™
Guidewires

Drug-Eluting Therapies

SYNERGY™ XD Stent System
Equipped with an innovative delivery system designed to make optimal healing even more deliverable

SYNERGY™ XD 48 mm Stent System
Designed to address the unique needs of long lesions

SYNERGY MEGATRON™ Stent System
Purpose-built DES for large proximal vessels

Learn more about coronary products
View the latest coronary product catalog

Coding and payment guides

Find additional information on coding, payment guides, and reimbursement information for inpatient, outpatient, office, and ASC settings.

View Interventional Cardiology reimbursement

Practical solutions for complex challenges

Boston Scientific is offering a growing selection of offerings specifically tailored to propel your cardiovascular business forward.

Learn more about our solutions

Contact Us

Get in touch with a sales representative to discuss how our portfolio of product and solutions can deliver measurable outcomes in the cardiovascular service line.

Contact Form

References:

**CY2021 CMS national base rate is $16,064 for APC 5194 vs. $10,043 for APC 5193. Actual rates will vary geographically and/or by individual facility
1. Presented by Pedro Lemos, MD at TCT2019
2. Kogame N, et al. J Am Coll Cardiol Intv. 2020;13:2251-62. DOI: 10.1016/j.jcin.2020.06.023
3. Presented by Giulio Stefanini, MD at EuroPCR 2021. This study evaluated the safety of the SYNERGY BP Stent with 1-month DAPT in high bleeding risk (HBR) patients
4. Pivato C.A., et al. J Am Heart Assoc. 2022;11:e023454. DOI: 10.1161/JAHA.121.023454
5. The SYNERGY BP Stent HBR indication is supported by the EVOLVE Short DAPT data. The HBR indication excludes SYNERGY XD 48 mm